Brean Downgrades United Therapeutics (UTHR) to Hold, Says Price Target Acheived
Tweet Send to a FriendGet Alerts UTHR Hot Sheet
Price: $69.17 --0%
Rating Summary:
3 Buy, 13 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 31 | New: 11
Rating Summary:
3 Buy, 13 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 31 | New: 11
Trade UTHR Now!
Brean Capital downgraded United Therapeutics Corp. (NASDAQ: UTHR) from Buy to Hold.
"We are downgrading United to Hold from Buy due to the achievement of our target price and our view that the next catalyst, a second FDA action on a refiled oral treprostinil application, will result in a second rejection. The resubmission of the oral treprostinil application was accepted, and it was not based on new data, but on the interpretation of existing data after an end-of-review meeting with the FDA. We also view United to have too few significant clinical or regulatory catalysts in the intermediate term after the upcoming FDA response to oral treprostinil," said analyst Jonathan Aschoff.
For an analyst ratings summary and ratings history on United Therapeutics Corp. (NASDAQ: UTHR)click here. For more ratings news on United Therapeutics Corp. click here.
Shares of United Therapeutics Corp. closed at $57.66 yesterday, with a 52 week range of $40.34-$59.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"We are downgrading United to Hold from Buy due to the achievement of our target price and our view that the next catalyst, a second FDA action on a refiled oral treprostinil application, will result in a second rejection. The resubmission of the oral treprostinil application was accepted, and it was not based on new data, but on the interpretation of existing data after an end-of-review meeting with the FDA. We also view United to have too few significant clinical or regulatory catalysts in the intermediate term after the upcoming FDA response to oral treprostinil," said analyst Jonathan Aschoff.
For an analyst ratings summary and ratings history on United Therapeutics Corp. (NASDAQ: UTHR)click here. For more ratings news on United Therapeutics Corp. click here.
Shares of United Therapeutics Corp. closed at $57.66 yesterday, with a 52 week range of $40.34-$59.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Goldman Sachs Downgrades Thoratec (THOR) to Neutral
- UBS Survey Shows Signs of Strength for Gilead's (GILD) TAF
- Deutsche Bank Raises PT on Access Midstream Partners (ACMP) to $57
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Downgrades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
